On 16 July 2025, The Lancet Respiratory Medicine published the results of the Phase III endTB‑Q study, the first clinical trial to focus exclusively on pre‑extensively drug‑resistant tuberculosis (pre‑XDR‑TB).
We are proud to share that Lorenzo Guglielmetti has been named to the 2025 TIME100 Health list, honoring the most influential people driving change and innovation in hea
On 29 January 2025, the New England Journal of Medicine (NEJM) published the manuscript of the endTB clinical trial results.
After 3 years of preparation, the endTB data is now open for requests!
The endTB consortium has completed endTB-Q, the first Phase 3 randomized controlled trial to exclusively enroll people with pre-extensively drug-resistant tuberculosis (pre-XDR-TB), a very hard-to-treat form of tuberculosis (TB).
We are happy to announce that the endTB-Q clinical trial results will be presented for the first time at the Union World Conference on Lung Health, in Bali, Indonesia, November 12-16.
An endTB-Q study participant at a clinic in Pakistan. Credit: Asim Hafeez
The endTB-Q clinical trial, led by Médecins Sans Frontières/Doctors Without Borders (MSF), Partners In Health
Socios En Salud is part of a global consortium that managed to shorten the treatment for patients with multidrug-resistant tuberculosis to nine months and without the use of injectables.
Have you ever heard about pre-XDR TB?
Six years after the launch of the endTB clinical trial, the results are now in! The trial offers multiple new shortened, all-oral drug regimens to treat adults and children with MDR-TB.
2023 Union World Conference on Lung Health, Paris, France
The endTB trial results will be presented, for the first time, at the Union World Conference on Lung Health, in Paris, France, on November 15-18.
You can find the details about the accepted sessions below. Join us at the conference!
________
Dr. Ninza Sheyo treats Khamokha Khamokha, a patient with MDR-TB, at PIH-supported Botsabelo Hospital in Maseru, Lesotho. Photo by Zack DeClerck/PIH
Tuberculosis (TB) is preventable and treatable. Despite this, 1.6 million people died from the infectious disease in 2021—a majority of whom live in low- and middle-income countries.
Medecins sans Frontieres (MSF) Counsellor Sagar Kumar Patra accompanying the patient to endTB clinic in Aundh Chest Hospital, Pune, India.
Médecins Sans Frontières/Doctors Without Borders (MSF), Partners In Health (PIH) and Interactive Research and Development (IRD), with funding from global health agency
endTB participant and Dra Jimena Ruiz, Hospital Nacional Sergio Bernales, Lima, Peru
The endTB clinical trial, funded by global health agency Unitaid, has reached another milestone.
Maya, a patient in Kazakhstan who accessed tuberculosis care through Partners In Health and the endTB project. Photo courtesy of Gulmira Tanatarova.
Maya* vividly remembers the day she received her diagnosis. As a 21-year-old college student in Astana, Kazakhstan, she’d been running persistent fevers and waking up drenched in sweat. Her mother insisted she get checked out.
Itumeleng Nkhabu, a patient enrolled in the endTB study, at her home in Lesotho. Photo by Mpho Marole / PIH
Itumeleng Nkhabu, a 48-year-old widow, contracted tuberculosis (TB) in 2003. Then again in 2011. That was not the last time she got sick.
In 2018, she was diagnosed with multidrug-resistant tuberculosis (MDR-TB), a severe form of the respiratory disease.
Anna Usova/MSF
Paris/Boston, 24 March 2023 – This World Tuberculosis (TB) Day, the endTB-Q clinical trial marks a critical milestone as the final patient enrolls in the study.
Gulnara Zhumakairova (center left) is among a small team of PIH Kazakhstan staff who connect tuberculosis patients with community organizations that provide food, diapers, and other support throughout their months of treatment. Photo courtesy of Gulnara Z
When a patient delivered her baby in the middle of her tuberculosis (TB) treatment, Gulnara Zhumakairova knew she would need to rally additional resources for the new mother, who was single and the sole caretaker of her newborn.
The endTB team welcomes the WHO Rapid Communication on updated guidance for the treatment of drug-resistant tuberculosis, which was released on 2 May 2022.1 This Rapid Communication continues a string of exciting advances in treatment for drug-resistant TB in recent years.
Atul Loke/Panos Pictures
Hindustan Time released a new article about endTB in India.
"Dr Lorenzo Guglielmetti is a doctor and the Médecins Sans Frontières director of the international endTB project. Dr Vijay Chavan is a chest specialist at the MSF TB Clinic in Mumbai.
credit photo : Atul Loke/Panos Pictures
Photos: Bithin Das / MDR-TB Treatment
BOSTON/PARIS, October 18, 2021 — 750 patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard med
Photo: Atul Loke/Panos Pictures
Paris – Médecins Sans Frontières / Doctors Without Borders (MSF), together with its partners, is happy to announce that the endTB clinical trials have started in India.
MDR-TB Treeatment preparation in the National Centre for Tuberculosis and Lung Disease in Tbilisi, Georgia
Results from the endTB Observational Study were published July 24, 2020, in the American Journal of Respiratory and Critical Care Medicine.
Participants to the 2nd endTB Clinical Trial In Person Meeting
After a first meeting in 2018, Médecins Sans Frontières, Sponsor of the endTB Clinical Trials, and its partners (PIH, IRD, HMS, ITM and Epicentre) have gathered for the second time the endTB Clinical Trial investigators and study coordinators in Paris.
(Photo: Jean-Pierre Amigo)
Karachi / Paris – Médecins Sans Frontières / Doctors Without Borders (MSF) and Interactive Research and Development (IRD) are pleased to announce the start of the endTB clinical trial in Pakistan
(Photo: Oksana Parafeniuk)
In March 2019, the endTB clinical trial celebrated a major milestone: the first participant completed participation in the trial. The patient, diagnosed with rifampin-resistant tuberculosis (RR-TB), started treatment and study participation in March 2017 in Tbilisi, Georgia.
endTB clinical trial investigators and study coordinators successfully complete first annual Investigators Meeting in Paris.
endTB clinical trial investigators and study coordinators successfully complete first annual Investigators Meeting in Paris.
Zugdidi TB Hospital, Georgia, 2017. Photo: Daro Sulakauri
South Africa has one of the highest burdens of TB and (Drug Resistant) DR-TB in the world, with around 20,000 people diagnosed with DR-TB in 2015. Photo: Sydelle WIllow Smith
(Graeme Williams/Unitaid)
Limpho Taka, a 47-year old patient with HIV and multidrug-resistant TB, (MDR-TB) lives in Mpokochela, a village in the Drakenberg mountains of Lesotho. It takes him three hours on his horse to reach the Bobete clinic where he receives treatment for MDR-TB.
(Photo: Daro Sulakauri)
An MSF clinician inspects a chest X-ray in Kyrgyzstan. (Pierre-Yves Bernard/MSF)
Médecins Sans Frontières / Doctors Without Borders (MSF) announces the closure of patient enrollment in the endTB clinical trial in Georgia.
Patient holding his medication, he takes up to 26 pills a day to treat XDR-TB. Here he holds his morning selection, which includes delamanid, one of the newest DR-TB drugs, which he is taking for the first time today.
Mzia Lekveishvili/Unitaid
Georgia continues to struggle with tuberculosis (TB), today’s leading infectious disease killer, and its drug-resistant forms. The homeless, unemployed, migrants, prisoners, and people who excessively consume alcohol are among the most affected.
Dr Iza Jikia (left) Dr Nino Dzidzikashvili (centre) review an DR-TB patient’s chest X-ray at the National Centre for Tuberculosis and Lung Disease in Georgia’s capital, Tbilisi. (Daro Sulakauri / MSF)
38 year old Yury had a form of TB that was resistant to both 1st and 2nd line TB drugs. After two years of treatment that wasn’t working, he was left with no other options, until MSF started a new program in the country in 2015. (Victoria Gendina / MSF)
Yury, 38, is celebrating a moment he thought would never arrive: he has been cured of a complicated form of Tuberculosis (TB), an infectious disease caused by mycobacteria which usually attacks the lungs.
Field technician Gaby Merlin Contreras provides the new TB drug, Bedaquiline, to a patient in Lima, Peru. (Photos by William Castro Rodríguez / Partners In Health)
For the first time in 50 years, two new drugs are available to patients battling the most trenchant forms of tuberculosis.
Nurses prepare patients’ treatments in the pharmacy of the ambulatory ward at the National Centre for Tuberculosis and Lung Disease in Georgia’s capital, Tbilisi.
TB doctor Irma Davitadze at work at the Regional Center of Infectious Pathology, AIDS and Tuberculosis in Batumi, a beach resort town on the Black Sea. MSF has worked here since 2014. (Daro Sulakauri)
Medical staff work in the ambulatory ward at the National Centre for Tuberculosis and Lung Disease in Georgia’s capital, Tbilisi. Patient Goderdzi Rajabishvili (left) recovers from his morning infusion of imipenem, an antibiotic drug used for the treatmen
A new tuberculosis drug, Bedaquiline, reaches Kazakhstan for the first time, thanks to Partners In Health's work on the endTB project. Photo by Yekaterina Sahabutdinova / Partners In Health
Diego (center, name changed), receives advice from PIH community health worker Verónica Quispe and PIH nursing technician Yecela Rodríguez at the Punchauca Health Center in Carabayllo, Peru. (William Castro Rodríguez / Socios En Salud)
Elizabeth Wangeci
Dr. Danny Puga (left), and Dr. KJ Seung (right) conduct an electrocardiogram on one of the first multidrug-resistant tuberculosis patients to be enrolled in the endTB project in Lesotho. (Photo: Lan Nguyen / Partners In Health)
MSF medical staff in Armenia review a patient's drug prescription. (Andrea Bussotti/MSF)
National TB Centre, Abovian, Armenia. Dr Shahidul Islam, an MSF TB doctor, examines a patient on the DR TB ward in the national TB centre. Many patients are unable to complete the grueling course of drugs. (Bruno De Cock / MSF)
